---
agent_readiness:
  band: agent-aware
  dimensions:
    agent_card: false
    agent_skills: derived
    agentic_access: false
    auth_clarity: true
    consent_identity: false
    dry_run_mode: false
    error_semantics: documented
    event_surface_described: false
    idempotency: false
    mcp_server: false
    openapi_examples: partial
    rate_limit_signal: false
    spec_presence: true
    well_known_catalog: false
  schema_version: 0.2
  score: 33.1
  scored_at: '2026-08-12'
api_count: 9
apis:
- description: Route, type, taxonomy and status discovery documents.
  name: Nacuity Pharmaceuticals Discovery API
  slug: nacuity-pharmaceuticals-discovery-api
- description: Media library (140 attachments at harvest time).
  name: Nacuity Pharmaceuticals Media API
  slug: nacuity-pharmaceuticals-media-api
- description: oEmbed 1.0 provider endpoint for nacuity.com URLs.
  name: Nacuity Pharmaceuticals Oembed API
  slug: nacuity-pharmaceuticals-oembed-api
- description: Corporate, clinical-programme and press-release pages (29 published at harvest time). Nacuity authors its news items as pages, not as posts.
  name: Nacuity Pharmaceuticals Pages API
  slug: nacuity-pharmaceuticals-pages-api
- description: The `portfolio` custom post type registered by the site theme and used for leadership entries. Registered and reachable, but empty (X-WP-Total 0).
  name: Nacuity Pharmaceuticals Portfolio API
  slug: nacuity-pharmaceuticals-portfolio-api
- description: Blog/news post collection. Registered and reachable, but empty (X-WP-Total 0) — every press release is a page under /news/.
  name: Nacuity Pharmaceuticals Posts API
  slug: nacuity-pharmaceuticals-posts-api
- description: Cross-content search across published objects.
  name: Nacuity Pharmaceuticals Search API
  slug: nacuity-pharmaceuticals-search-api
- description: Yoast SEO head-tag rendering for a nacuity.com URL — the only anonymously readable operation in the yoast/v1 namespace.
  name: Nacuity Pharmaceuticals Seo API
  slug: nacuity-pharmaceuticals-seo-api
- description: Categories, tags and the `portfolio-types` custom taxonomy. Categories holds one term (Uncategorized, count 0); tags is empty; portfolio-types holds one term (leadership, count 0).
  name: Nacuity Pharmaceuticals Taxonomy API
  slug: nacuity-pharmaceuticals-taxonomy-api
artifact_total: 12
common:
- group: other
  title: ''
  type: Overlay
  url: overlays/nacuity-pharmaceuticals-content-overlay.yaml
- group: company
  title: ''
  type: Website
  url: https://www.nacuity.com/
- group: company
  title: ''
  type: About
  url: https://www.nacuity.com/about/
- group: other
  title: ''
  type: Science
  url: https://www.nacuity.com/our-science/
- group: other
  title: ''
  type: Pipeline
  url: https://www.nacuity.com/pipeline/
- group: other
  title: ''
  type: DevelopmentPrograms
  url: https://www.nacuity.com/development-programs/
- group: company
  title: ''
  type: Investors
  url: https://www.nacuity.com/investors-collaborators/
- group: company
  title: ''
  type: News
  url: https://www.nacuity.com/news/
- group: company
  title: ''
  type: BlogRSS
  url: https://www.nacuity.com/feed/
- group: other
  title: ''
  type: MedicalInformation
  url: https://www.nacuity.com/medical-information/
- group: other
  title: ''
  type: Publications
  url: https://www.nacuity.com/publications/
- group: other
  title: ''
  type: ExpandedAccess
  url: https://www.nacuity.com/expanded-access-policy/
- group: docs
  title: ''
  type: References
  url: https://www.nacuity.com/references/
- group: operate
  title: ''
  type: Contact
  url: https://www.nacuity.com/contact/
- group: operate
  title: ''
  type: Support
  url: https://www.nacuity.com/contact/
- group: commercial
  title: ''
  type: PrivacyPolicy
  url: https://www.nacuity.com/privacy-policy/
- group: other
  title: ''
  type: Disclaimer
  url: https://www.nacuity.com/disclaimer/
- group: company
  title: ''
  type: LinkedIn
  url: https://www.linkedin.com/company/nacuity-pharmaceuticals-inc/
- group: company
  title: ''
  type: Twitter
  url: https://x.com/nacuitypharma
- group: other
  title: ''
  type: Sitemap
  url: https://www.nacuity.com/sitemap_index.xml
- group: other
  title: ''
  type: SecondaryMarket
  url: https://forgeglobal.com/nacuity-pharmaceuticals_stock/
- group: auth
  title: ''
  type: Authentication
  url: authentication/nacuity-pharmaceuticals-authentication.yml
- group: design
  title: ''
  type: Conventions
  url: conventions/nacuity-pharmaceuticals-conventions.yml
- group: design
  title: ''
  type: Conformance
  url: conformance/nacuity-pharmaceuticals-conformance.yml
- group: design
  title: ''
  type: ErrorCatalog
  url: errors/nacuity-pharmaceuticals-problem-types.yml
- group: design
  title: ''
  type: Lifecycle
  url: lifecycle/nacuity-pharmaceuticals-lifecycle.yml
- group: design
  title: ''
  type: DataModel
  url: data-model/nacuity-pharmaceuticals-data-model.yml
- group: design
  title: ''
  type: JSONLD
  url: json-ld/nacuity-pharmaceuticals-json-ld.yml
- group: agent
  title: ''
  type: WellKnown
  url: well-known/nacuity-pharmaceuticals-well-known.yml
- group: auth
  title: ''
  type: DomainSecurity
  url: security/nacuity-pharmaceuticals-domain-security.yml
- group: agent
  title: ''
  type: LLMsTxt
  url: llms/nacuity-pharmaceuticals-llms.txt
- group: agent
  title: ''
  type: AgentSkill
  url: skills/_index.yml
created: '2026-08-04'
description: Nacuity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Fort Worth, Texas, with operations in Carlton South, Victoria, Australia. It develops targeted therapeutics against oxidative stress, the mechanism it holds responsible for a family of blinding eye diseases and chronic conditions. Its lead asset, NPI-001 (N-acetylcysteine amide) tablets, is in development for retinitis pigmentosa and holds U.S. FDA Breakthrough Therapy, Fast Track and Orphan Drug designations; the SLO-RP Phase 1/2 trial reported significantly lower photoreceptor loss than placebo from six months through the 24-month study in retinitis pigmentosa associated with Usher syndrome. A second programme, NPI-002, is an intravitreal implant for the delay of cataract progression and has completed implantation in the final cohort of its Phase 1/2 trial. A third programme addresses cystinosis. The company licensed its founding technology from Johns Hopkins University, is backed
  by Foundation Fighting Blindness and its venture arm the RD Fund, and partners with Arctic Therapeutics on AT-001 for hereditary cystatin C amyloid angiopathy. Nacuity Pharmaceuticals runs no developer program and publishes no product API, no developer portal and no API documentation; the only machine-readable surface reachable without credentials is the WordPress REST content API behind www.nacuity.com, catalogued here.
image: https://www.nacuity.com/wp-content/uploads/2017/03/nacuity-pharmaceuticals-inc_web.png
jsonld:
- class_count: 0
  name: Nacuity Pharmaceuticals Organization Context
  property_count: 0
  slug: nacuity-pharmaceuticals-organization
layout: provider
modified: '2026-08-04'
name: Nacuity Pharmaceuticals
nav: Providers
network: true
overview: 'Nacuity Pharmaceuticals publishes 9 APIs on the [APIs.io](https://apis.io/) network, including Discovery API, Media API, Oembed API, and 6 more. Tagged areas include Company, biopharmaceuticals, pharmaceuticals, ophthalmology, and rare-disease.


  The Nacuity Pharmaceuticals catalog on APIs.io includes 1 JSON-LD context.


  Nacuity Pharmaceuticals'' developer surface includes product news, support, authentication, and 29 more developer resources.'
random_paper: 0
score:
  band: thin
  composite: 29.1
  delta: 0.0
  facets:
    commercial_clarity: 10.5
    contract_quality: 58.4
    developer_ergonomics: 16.8
    discoverability: 81.5
    governance: 11.5
    operational_transparency: 0.0
  previous_composite: 29.1
  provenance:
    conformance: derived
    contracts:
      callable: 100.0
      derived: 0
      marker_coverage: 0.0
      total: 9
    skills: derived
  regulatory:
    applies: true
    matched_via: tags
    regime: Health
    regime_id: health
    score: 26.3
  schema_version: 0.11.0
  scored_at: '2026-08-12'
  trend: flat
screenshot: https://raw.githubusercontent.com/api-evangelist/nacuity-pharmaceuticals/refs/heads/main/screenshots/nacuity-pharmaceuticals-2026-08-07T184606.png
security:
- kind: authentication
  name: Nacuity Pharmaceuticals Authentication
  slug: nacuity-pharmaceuticals-authentication
  summary_line: 0 schemes
- kind: domain-security
  name: Nacuity Pharmaceuticals Domain Security
  slug: nacuity-pharmaceuticals-domain-security
  summary_line: TLSv1.3 · DMARC
slug: nacuity-pharmaceuticals
tags:
- Company
- biopharmaceuticals
- pharmaceuticals
- ophthalmology
- rare-disease
- clinical-trials
- retinitis-pigmentosa
- oxidative-stress
- life-sciences
- drug-development
- content-api
website: https://www.nacuity.com/
---
